Leard Lorriana E, Cho Bryan K, Jones Kirk D, Hays Steven R, Tope Whitney D, Golden Jeffrey A, Hoopes Charles W
Division of Pulmonary and Critical Care Medicine, University of California at San Francisco, San Francisco, California 94143-0111, USA.
J Heart Lung Transplant. 2007 Dec;26(12):1340-4. doi: 10.1016/j.healun.2007.09.019.
Organ transplant recipients are at increased risk for aggressive cutaneous squamous cell carcinomas (cSCC) that recur and metastasize despite treatment with surgery, radiation, or both. Therapies targeting the epidermal growth factor receptor (EGFR) are being explored as treatments for metastatic cSCC. We describe our experience with two single-lung transplant patients who developed metastatic cSCC; failed surgical resection, radiation or chemoradiation therapy; and were ultimately treated with an EGFR inhibitor, cetuximab. Both patients died shortly after initiation of cetuximab due to diffuse alveolar damage, suggesting that EGFR inhibitors should be used with extreme caution in lung transplant recipients.
器官移植受者发生侵袭性皮肤鳞状细胞癌（cSCC）的风险增加，尽管接受了手术、放疗或两者联合治疗，这些癌症仍会复发和转移。针对表皮生长因子受体（EGFR）的疗法正在被探索用于转移性cSCC的治疗。我们描述了两名单肺移植患者发生转移性cSCC的经历；手术切除、放疗或放化疗均失败；最终接受了EGFR抑制剂西妥昔单抗治疗。两名患者在开始使用西妥昔单抗后不久均因弥漫性肺泡损伤死亡，这表明在肺移植受者中应极其谨慎地使用EGFR抑制剂。
